LYRA vs. OM, MODD, NXL, BDMD, CLGN, MBOT, TMDIF, MDAI, NMTC, and FEMY
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Outset Medical (OM), Modular Medical (MODD), Nexalin Technology (NXL), Baird Medical Investment (BDMD), CollPlant Biotechnologies (CLGN), Microbot Medical (MBOT), Titan Medical (TMDIF), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), and Femasys (FEMY). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs.
Lyra Therapeutics (NASDAQ:LYRA) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.
Lyra Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.
95.6% of Lyra Therapeutics shares are owned by institutional investors. 4.7% of Lyra Therapeutics shares are owned by insiders. Comparatively, 4.1% of Outset Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Lyra Therapeutics presently has a consensus price target of $4.50, suggesting a potential upside of 2,087.65%. Outset Medical has a consensus price target of $4.50, suggesting a potential upside of 414.05%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than Outset Medical.
Outset Medical has a net margin of -112.57% compared to Lyra Therapeutics' net margin of -6,635.76%. Lyra Therapeutics' return on equity of -125.07% beat Outset Medical's return on equity.
In the previous week, Outset Medical had 17 more articles in the media than Lyra Therapeutics. MarketBeat recorded 17 mentions for Outset Medical and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 beat Outset Medical's score of -0.16 indicating that Lyra Therapeutics is being referred to more favorably in the media.
Lyra Therapeutics has higher earnings, but lower revenue than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lyra Therapeutics and Outset Medical both received 24 outperform votes by MarketBeat users. However, 60.00% of users gave Lyra Therapeutics an outperform vote while only 38.71% of users gave Outset Medical an outperform vote.
Summary
Lyra Therapeutics beats Outset Medical on 9 of the 16 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free LYRA Stock Alerts